John Thero (Christopher Goodney/Bloomberg via Getty Images)

Amarin CEO John Thero pass­es ba­ton to Eu­rope com­mer­cial chief as M&A hopes con­tin­ue to de­flate

As Amarin breaks in­to the Eu­ro­pean mar­ket, John Thero is head­ing out.

Af­ter steer­ing the ship for 7 years, Thero is hand­ing the CEO job to Karim Mikhail, who came on board ear­li­er this year to head the com­mer­cial­iza­tion of Amarin’s fish oil pill in Eu­rope. Mikhail’s ap­point­ment is ef­fec­tive Aug. 1, when Thero will of­fi­cial­ly re­tire and tran­si­tion to an ad­vi­sor role un­til the end of 2021.

Since join­ing Amarin in 2009, Thero has been cred­it­ed for a slate of achieve­ments that gave in­vestors lots to be ex­cit­ed about. Un­der his watch, Vas­cepa — the phar­ma­ceu­ti­cal grade omega-3 fat­ty acid prod­uct first ap­proved in 2012 — was cruised to a pos­i­tive Phase III da­ta read­out de­spite some con­tro­ver­sy, spurring an im­pres­sive re­duc­tion in risk of car­dio­vas­cu­lar events that led to a quick FDA add-on ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.